Innova Captab Limited - Asset Resilience Ratio

Latest as of March 2026: 2.25%

Innova Captab Limited (INNOVACAP) has an Asset Resilience Ratio of 2.25% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Also explore INNOVACAP total asset value for the complete picture of this company's asset base.

Liquid Assets

Rs412.85 Million
≈ $4.46 Million USD Cash + Short-term Investments

Total Assets

Rs18.37 Billion
≈ $198.71 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2019–2026)

This chart shows how Innova Captab Limited's Asset Resilience Ratio has changed over time. See Innova Captab Limited (INNOVACAP) net asset quality to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Innova Captab Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see INNOVACAP stock market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Rs0.00 0%
Short-term Investments Rs412.85 Million 2.25%
Total Liquid Assets Rs412.85 Million 2.25%

Asset Resilience Insights

  • Limited Liquidity: Innova Captab Limited maintains only 2.25% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Innova Captab Limited Industry Peers by Asset Resilience Ratio

Compare Innova Captab Limited's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
Drug Manufacturers - Specialty & Generic 4.94%
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
Drug Manufacturers - Specialty & Generic 0.16%
Takeda Pharmaceutical Company Limited
F:TKDA
Drug Manufacturers - Specialty & Generic 0.69%
Ajanta Pharma Limited
NSE:AJANTPHARM
Drug Manufacturers - Specialty & Generic 14.99%
Kangmei Pharmaceutical Co Ltd
SHG:600518
Drug Manufacturers - Specialty & Generic 0.00%
Cronos Group Inc
TO:CRON
Drug Manufacturers - Specialty & Generic 69.94%
Guizhou Bailing Group Pharmaceutical Co Ltd
SHE:002424
Drug Manufacturers - Specialty & Generic 2.09%
Dezhan HealthCare Co Ltd
SHE:000813
Drug Manufacturers - Specialty & Generic 0.15%

Annual Asset Resilience Ratio for Innova Captab Limited (2019–2026)

The table below shows the annual Asset Resilience Ratio data for Innova Captab Limited.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2026-03-31 2.25% Rs412.85 Million
≈ $4.46 Million
Rs18.37 Billion
≈ $198.71 Million
-0.90pp
2025-03-31 3.15% Rs497.62 Million
≈ $5.38 Million
Rs15.80 Billion
≈ $170.92 Million
-2.33pp
2024-03-31 5.48% Rs723.64 Million
≈ $7.83 Million
Rs13.21 Billion
≈ $142.85 Million
+5.13pp
2023-03-31 0.34% Rs35.00 Million
≈ $378.51K
Rs10.19 Billion
≈ $110.17 Million
+0.22pp
2022-03-31 0.13% Rs7.23 Million
≈ $78.19K
Rs5.75 Billion
≈ $62.24 Million
-1.80pp
2021-03-31 1.92% Rs70.99 Million
≈ $767.73K
Rs3.70 Billion
≈ $39.97 Million
+0.62pp
2020-03-31 1.30% Rs49.45 Million
≈ $534.78K
Rs3.80 Billion
≈ $41.08 Million
+0.39pp
2019-03-31 0.92% Rs30.12 Million
≈ $325.74K
Rs3.29 Billion
≈ $35.53 Million
--
pp = percentage points

About Innova Captab Limited

NSE:INNOVACAP India Drug Manufacturers - Specialty & Generic
Market Cap
$523.68 Million
Rs48.42 Billion INR
Market Cap Rank
#12317 Global
#583 in India
Share Price
Rs846.20
Change (1 day)
+0.32%
52-Week Range
Rs644.75 - Rs945.45
All Time High
Rs1240.00
About

Innova Captab Limited, an integrated pharmaceutical company, engages in the research and development, manufacture, distribution, and marketing of drugs in India and internationally. The company provides contract development and manufacturing organization services to Indian pharmaceutical companies. It is also offers various generic formulation products, including cephalosporins, proton pump inhib… Read more